Profile's ShareData Online
Offshore Trusts
ManCo List
Funds by Name
Funds by Category
Word Search
FAQ
Franklin Biotechnology Discovery Fund
Franklin Biotechnology Discovery Fund
Franklin Templeton Investment Funds
Franklin Biotechnology Discovery Fund
News
Regional Portfolio Structure(Semi-Annual Comparison)
Sectorial Portfolio Structure(Semi-Annual Comparison)
Price
 
Ranking
Sector: USA-Equity-Unclassified
Size: (USD) 1 590 000 000
 
Sector Rank: 1 out of 3
(lump sum over 3 years to 30 Nov 2024)
 
Overall Rank: 152 out of 485
(lump sum over 3 years to 30 Nov 2024)
 
R20000 invested on 30 Nov 2021 was worth R25 627 at 30 Nov 2024
(8.61% annual compound return)
 
R5000 per month since 30 Nov 2021 was worth R223 096 at 30 Nov 2024
(13.56% annual return compounded monthly)
 
Please note that offshore fund performance figures are calculated from NAV prices (ie, equivalent to sell-to-sell) and therefore not directly comparable to domestic fund performance figures on this site.
 
Management
Evan McCulloch, CFA, Franklin Advisors Inc
Evan McCulloch is a vice president and portfolio manager for Franklin Advisers, Inc. He manages the Franklin Biotechnology Discovery Fund and the Franklin Biotechnology Fund. Mr McCulloch also specialises in research analysis of the health care industry; including pharmaceuticals, health care information systems/internet and health care providers. Mr McCulloch joined Franklin Templeton Investments in 1992 as a management trainee. He received a bachelor's degree in economics from the University of California at Berkeley. He is a Chartered Financial Analyst (CFA) and a member of the Association for Investment Management and Research (AIMR) and the Security Analysts of San Francisco (SAs/f).
 
Steve Kornfeld
 
Christopher Jay Lee
 
Wendy Lam
 
Akiva Felt
 
Focus and Objective
The investment objective of the fund is capital growth by investing in equity securities of biotechnology companies and discovery research firms mainly located in the USA substantial portion of its assets will be in smaller capitalisation companies (those with market capitalisation of less than USD2bn). For the fund's investment purposes, a biotechnology company is one that has at least 50% of its earnings derived from biotechnology activities, or at least 50% of its assets devoted to such activities based on the company's most recent fiscal year. Biotechnology activities are research, development, manufacture and distribution of various biotechnological or biomedical products, services and processes. This may include companies involved with genomics, genetic engineering and gene therapy. It also includes companies involved in the application and development of biotechnology in areas such as health care, pharmaceuticals and agriculture. To the extent that the fund invests in debt securities, it generally buys securities that are rated investment grade or unrated securities that it determines to be of comparable quality. Investment grade debt securities are rated in the top four ratings categories by independent ratings organisations such as Standard & Poor's Corporation or Moody's Investors Service Inc. The fund anticipates that under normal conditions, it will invest more of its assets in US securities than in those of any other single country although the fund may have more than 50% of its total assets in non-US securities. The manager may take a temporary defensive position when it believes the securities trading markets or the economies of countries where the fund invests are experiencing excessive volatility or prolonged general decline, or other adverse conditions exist. Under these circumstances, the fund may be unable to pursue its investment goal.
 
Technical Overview
Benchmark: NASDAQ Biotechnology index
Administration Fee Management fee (p.a.): 1.51%
Allows debit orders No Maximum Exit Fee
Annual Registrar Fee 0.20% Minimum lump sum: $5 000
Base currency: USD Minimum monthly: $1 000
Broker Comm. Payable Yes Minimum Exit Fee
Custodian Fee Number of holdings: 65
Domicile Luxembourg Original price: USD 100.00
Exit fee charge: No Performance fee:
Formation date: 03 Apr 2000 Pricing system: Forward
Is this fund a roll-up? Yes Promotional Fee
 
Top holdings on 30 Sep 2024
Share (Sector) Value (USD) % of fund
AMGEN (Healthcare) 129 744 000 8.16%
REGENERONPHA (Healthcare) 113 367 000 7.13%
VERTEXPHARM (Healthcare) 92 697 000 5.83%
GILD.US () 58 671 000 3.69%
ASTRAZENECA (Healthcare) 46 428 000 2.92%
BIOGENINC (Healthcare) 43 566 000 2.74%
TOTALS 484 473 000 30.47%

Site Last Updated: 23 December 2024
© 1999-2006
Profile Media . All rights reserved.
JSE and the JSE logo are trade marks of the JSE.
Legal Notices | PAIA Manual